Roche signs another antibiotic deal
This article was originally published in Scrip
Executive Summary
Roche has signed its second deal in the antibiotic space in four months, announcing a new collaboration with a privately owned UK biotech firm, Discuva. The latter has developed a new approach to discovering antibiotics aimed at speeding up the process, and it is focused on new products to target the toughest pathogens that are resistant to other drugs.